AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8120158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-loading (P-L) group received 150 and 200 mg of clomipramine (CMI) on two consecutive evenings, then placebo for 8 days
Number of subjects: 32
Study 8120158 — intervention group
Group type: COMPARATOR
Intervention: Traditional group began at 50 mg of CMI, followed by gradual increases every second day until 200 mg was reached
Number of subjects: 32
Study 8120158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-loading (P-L) group
Number of subjects: 32
Study 3321413 — intervention group
Group type: EXPERIMENTAL
Intervention: LAF + PSA (decontamination, isolation in a laminar air flow room and prophylactic systemic antibiotics)
Number of subjects: 99
Study 3321413 — intervention group
Group type: COMPARATOR
Intervention: PSA (prophylactic systemic antibiotics in a conventional hospital room)
Number of subjects: 99
Study 3321413 — intervention group
Group type: EXPERIMENTAL
Intervention: LAF + PSA
Number of subjects: 99
Study 3321413 — intervention group
Group type: COMPARATOR
Intervention: PSA
Number of subjects: 99
Study 30423420 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA, anode over left dorsolateral prefrontal cortex, cathode over left temporoparietal cortex)
Number of subjects: 48
Study 30423420 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 48
Study 27939229 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV in bilevel mode
Number of subjects: 13
Study 27939229 — intervention group
Group type: COMPARATOR
Intervention: Sham ventilation (continuous positive airway pressure mode, 4 cm H2O)
Number of subjects: 13
Study 25645191 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential-oil extract of Cretan aromatic plants (0.5ml soft gel capsules, twice a day for 7 days)
Number of subjects: 105
Study 25645191 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5ml olive oil in soft gel capsules)
Number of subjects: 105
Study 25645191 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential-oil extract of Cretan aromatic plants
Number of subjects: 105
Study 25645191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 23895706 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/multimineral supplement
Number of subjects: 240
Study 23895706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 21809218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone-based counseling intervention for 18 months
Number of subjects: 249
Study 21809218 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 249
Study 21809218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone-based counseling intervention with increased exposure
Number of subjects: 249
Study 19644434 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive (IS) drugs
Number of subjects: 26
Study 19644434 — intervention group
Group type: COMPARATOR
Intervention: No immunosuppressive (IS) drugs
Number of subjects: 26
Study 19644434 — intervention group
Group type: EXPERIMENTAL
Intervention: SOF patients
Number of subjects: 26
Study 19644434 — intervention group
Group type: EXPERIMENTAL
Intervention: MOF patients
Number of subjects: 26
Study 19644434 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro LPS stimulation
Number of subjects: 26
Study 19644434 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma replacement by milieu
Number of subjects: 26
Study 17451567 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg b.d.
Number of subjects: 100
Study 17451567 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg t.d.s. plus Omeprazole 20 mg o.d.
Number of subjects: 100
Study 17451567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15247521 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for prevention and cure from JCP in 1998 (non-pollination season)
Number of subjects: 820
Study 15247521 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for prevention and cure from JCP in 2003 (pollination season)
Number of subjects: 820
Study 15247521 — intervention group
Group type: COMPARATOR
Intervention: Comparison of WTP values between 1998 and 2003
Number of subjects: 820
Study 11559718 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily for 4 months
Number of subjects: 100
Study 11559718 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg daily for 4 months
Number of subjects: 100
Study 11559718 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole for tumors positive for ErbB‐1 and/or ErbB‐2 and ER
Number of subjects: 100
Study 11559718 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen for tumors positive for ErbB‐1 and/or ErbB‐2 and ER
Number of subjects: 100
Study 9152671 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 9152671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 9152671 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 0
Study 8177688 — intervention group
Group type: EXPERIMENTAL
Intervention: Signed language systems (three different systems)
Number of subjects: 27
Study 8177688 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 3665523 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium entry blocker nicardipine
Number of subjects: 383
Study 3665523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 31378952 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa Benserazide (LDB) generic preparation (Teva Italia)
Number of subjects: 43
Study 31378952 — intervention group
Group type: COMPARATOR
Intervention: Madopar (originator)
Number of subjects: 43
Study 27935557 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable tubing assistive walking device (WTAWD)
Number of subjects: 0
Study 27935557 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 0
Study 27935557 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastic band orthosis
Number of subjects: 0
Study 26477840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab given monthly
Number of subjects: 2457
Study 26477840 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg or 2 mg intravitreal aflibercept injection given monthly
Number of subjects: 2457
Study 26477840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravitreal aflibercept given every other month after 3 initial monthly doses
Number of subjects: 2457
Study 26477840 — intervention group
Group type: COMPARATOR
Intervention: Capped pro re nata (PRN) regimen
Number of subjects: 2457
Study 23262496 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin (10 mg/d)
Number of subjects: 31
Study 23262496 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 21320764 — intervention group
Group type: EXPERIMENTAL
Intervention: Williams syndrome individuals (WS)
Number of subjects: 15
Study 21320764 — intervention group
Group type: COMPARATOR
Intervention: Normal developing individuals (matched for CA)
Number of subjects: 15
Study 21320764 — intervention group
Group type: COMPARATOR
Intervention: Normal developing individuals (matched for MA)
Number of subjects: 15
Study 19850808 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee height +20 cm
Number of subjects: 24
Study 19850808 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee height +10 cm
Number of subjects: 24
Study 19850808 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee height
Number of subjects: 24
Study 19850808 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee height -10 cm
Number of subjects: 24
Study 19850808 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee height -20 cm
Number of subjects: 24
Study 16118646 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based environmental obesity prevention program
Number of subjects: 450
Study 12646106 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 249
Study 12646106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazol
Number of subjects: 249
Study 12646106 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 249
Study 11192954 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking training
Number of subjects: 46
Study 11192954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 46
Study 8873687 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, 40 mg/day
Number of subjects: 15
Study 8873687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1382159 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg once daily for 7 days
Number of subjects: 16
Study 1382159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3929201 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg of penicillin V
Number of subjects: 100
Study 3929201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 31884836 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether emulsion (1%)
Number of subjects: 73
Study 31884836 — intervention group
Group type: COMPARATOR
Intervention: Fusidic acid emulsion (5g: 0.1g)
Number of subjects: 73
Study 31868905 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 592
Study 31868905 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus bevacizumab
Number of subjects: 592
Study 31868905 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab
Number of subjects: 592
Study 29740026 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically determined risk of CAD
Number of subjects: 67809
Study 29740026 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of the APOE locus
Number of subjects: 67809
Study 26984449 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 582
Study 26984449 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 582
Study 24912456 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPPS (Systems Training for Emotional Predictability and Problem Solving) added to treatment as usual (TAU) for BD
Number of subjects: 0
Study 24912456 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) for BD
Number of subjects: 0
Study 22434467 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 100
Study 22434467 — intervention group
Group type: COMPARATOR
Intervention: Mosaicplasty
Number of subjects: 100
Study 20411863 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluation using video recording of Foley catheterization
Number of subjects: 40
Study 20411863 — intervention group
Group type: COMPARATOR
Intervention: Written evaluation guidelines only
Number of subjects: 40
Study 18826866 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 20 mg/kg coadministered with digoxin
Number of subjects: 16
Study 18826866 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 16
Study 15701493 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 84
Study 15701493 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy (Milligan-Morgan technique)
Number of subjects: 84
Study 12776949 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-dosage Group (3 mg/kg of heparin)
Number of subjects: 16
Study 12776949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage Group (1.5 mg/kg of heparin)
Number of subjects: 16
Study 12776949 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 16
Study 10979947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg/d) for 75 days after BMT
Number of subjects: 300
Study 10979947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8791964 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg
Number of subjects: 16
Study 8791964 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 16
Study 1447585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest Discomfort Diary (experimental group)
Number of subjects: 31
Study 1447585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no diary)
Number of subjects: 31
Study 3979665 — intervention group
Group type: EXPERIMENTAL
Intervention: Free choice
Number of subjects: 2
Study 3979665 — intervention group
Group type: COMPARATOR
Intervention: Forced choice
Number of subjects: 2
Study 3979665 — intervention group
Group type: COMPARATOR
Intervention: Delays
Number of subjects: 2
Study 31722701 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot morphological variables (Clarke's angle, Wejsflog index, hallux valgus angle, foot width) in girls
Number of subjects: 200
Study 31722701 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot morphological variables (Clarke's angle, Wejsflog index, foot width) in boys
Number of subjects: 200
Study 30541089 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 180
Study 26564430 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin
Number of subjects: 34
Study 26564430 — intervention group
Group type: COMPARATOR
Intervention: Control (no platelet-rich fibrin)
Number of subjects: 34
Study 25218337 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus capecitabine 1000mg/m(2) twice daily and cisplatin 80 mg/m(2) on day 1 every 3 weeks
Number of subjects: 244
Study 25218337 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus capecitabine 1000mg/m(2) twice daily and cisplatin 80 mg/m(2) on day 1 every 3 weeks
Number of subjects: 244
Study 22337582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 20
Study 22337582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20223367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 177
Study 20223367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 177
Study 20223367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 177
Study 20223367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 20223367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (maximum allowed dose of 20 mg)
Number of subjects: 177
Study 20223367 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 177
Study 18274222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose exercise (20 min/day, 5 days/week for 15 weeks)
Number of subjects: 94
Study 18274222 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (40 min/day, 5 days/week for 15 weeks)
Number of subjects: 94
Study 18274222 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 94
Study 15604120 — intervention group
Group type: EXPERIMENTAL
Intervention: Full funding for breast prosthesis
Number of subjects: 102
Study 11384079 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (FOS) 10 mg
Number of subjects: 30
Study 11384079 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (CAP) 6.25 mg
Number of subjects: 30
Study 11384079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9232343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 units/day)
Number of subjects: 30
Study 9232343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 30
Study 7907184 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining the same dose of the neuroleptic over an extended trial
Number of subjects: 0
Study 7907184 — intervention group
Group type: EXPERIMENTAL
Intervention: Significantly increasing the dose of the same neuroleptic
Number of subjects: 0
Study 7907184 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to a different class of neuroleptic
Number of subjects: 0
Study 7907184 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative symptoms and acute extrapyramidal side effects (EPS)
Number of subjects: 0
Study 3300139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fusidic acid (Fucithalmic), given twice daily
Number of subjects: 164
Study 2791372 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate-responsive (RR) pacing mode
Number of subjects: 16
Study 2791372 — intervention group
Group type: COMPARATOR
Intervention: Constant rate (VVI) pacing mode
Number of subjects: 16
Study 2791372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham Health Profile (quality of life assessment)
Number of subjects: 16
Study 238413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of lorazepam
Number of subjects: 22
Study 238413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30885824 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) treatment
Number of subjects: 69
Study 30885824 — intervention group
Group type: COMPARATOR
Intervention: No Erythropoietin (EPO) treatment (Control)
Number of subjects: 69
Study 28665874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection PVB at T3-T4 level with 25 mL of 0.5% ropivacaine and 4 subcutaneous sham injections
Number of subjects: 70
Study 28665874 — intervention group
Group type: COMPARATOR
Intervention: Multiple-injection PVB from T1 to T5 level with 5 mL of 0.5% ropivacaine injected at each level
Number of subjects: 70
Study 28665874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection PVB
Number of subjects: 70
Study 28665874 — intervention group
Group type: COMPARATOR
Intervention: Multiple-injection PVB
Number of subjects: 70
Study 25952354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nominated friends targeting method
Number of subjects: 5773
Study 25952354 — intervention group
Group type: COMPARATOR
Intervention: Randomly selected villagers targeting method
Number of subjects: 5773
Study 25952354 — intervention group
Group type: COMPARATOR
Intervention: Indegree targeting method
Number of subjects: 5773
Study 23861303 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 637
Study 23861303 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 637
Study 23861303 — intervention group
Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX (in patients with CRP >1.0 mg/dl)
Number of subjects: 637
Study 23861303 — intervention group
Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 637
Study 21653575 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 99
Study 21653575 — intervention group
Group type: COMPARATOR
Intervention: ADA diet
Number of subjects: 99
Study 19348963 — intervention group
Group type: EXPERIMENTAL
Intervention: personal digital assistant‐based cholesterol management intervention
Number of subjects: 61
Study 19348963 — intervention group
Group type: COMPARATOR
Intervention: intervention similar in intensity and frequency of contact focused on hypertension clinical practice guideline
Number of subjects: 61
Study 16920893 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 mg for nonsmokers; 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, and 10.0 mg for smokers)
Number of subjects: 6
Study 16920893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 15113632 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast‐fed and 1‐ml 30% glucose
Number of subjects: 120
Study 15113632 — intervention group
Group type: COMPARATOR
Intervention: Breast‐fed and 1‐ml placebo
Number of subjects: 120
Study 15113632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting and 1‐ml 30% glucose
Number of subjects: 120
Study 15113632 — intervention group
Group type: COMPARATOR
Intervention: Fasting and 1‐ml placebo
Number of subjects: 120
Study 11641032 — intervention group
Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA) infants
Number of subjects: 318
Study 11641032 — intervention group
Group type: COMPARATOR
Intervention: Appropriate for gestational age (AGA) infants
Number of subjects: 318
Study 9333792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel therapy with a fixed inspiratory to expiratory pressure ratio of 1:0.6
Number of subjects: 52
Study 9333792 — intervention group
Group type: COMPARATOR
Intervention: CPAP therapy
Number of subjects: 52
Study 9333792 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel therapy
Number of subjects: 52
Study 8498624 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-lesson curriculum focused on drug resistance skills
Number of subjects: 4000
Study 8498624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4000
Study 8498624 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-lesson curriculum
Number of subjects: 4000
Study 3328906 — intervention group
Group type: COMPARATOR
Intervention: Auranofin orally
Number of subjects: 46
Study 3328906 — intervention group
Group type: EXPERIMENTAL
Intervention: Allochrysine intramuscularly
Number of subjects: 46
Study 29948176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 0.15% + brilliant blue 0.05% + lutein 2% (Group 1)
Number of subjects: 45
Study 29948176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 0.15% + brilliant blue 0.025% + polyethylene glycol 3350 4% (Group 2)
Number of subjects: 45
Study 29948176 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green 0.05% (Group 3)
Number of subjects: 45
Study 26944693 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational programme
Number of subjects: 100
Study 26944693 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus regular sedation quality feedback using process control charts
Number of subjects: 100
Study 26944693 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus a novel sedation monitoring technology
Number of subjects: 100
Study 26944693 — intervention group
Group type: EXPERIMENTAL
Intervention: All three interventions
Number of subjects: 100
Study 26944693 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 26944693 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 100